{"id":71768,"date":"2026-08-06T00:23:22","date_gmt":"2026-08-05T16:23:22","guid":{"rendered":"https:\/\/flcube.com\/?p=71768"},"modified":"2026-08-06T00:23:23","modified_gmt":"2026-08-05T16:23:23","slug":"bayer-reports-q2-2026-sales-of-eur-10-87b-driven-by-strong-nubeqa-and-kerendia-growth-despite-xarelto-and-eylea-patent-expirations","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71768","title":{"rendered":"Bayer Reports Q2 2026 Sales of EUR 10.87B, Driven by Strong Nubeqa and Kerendia Growth Despite Xarelto and Eylea Patent Expirations"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Bayer AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/BAYN:ETR\">ETR: BAYN<\/a>) released its financial results for the second quarter of 2026, reporting <strong>group sales of EUR 10.872 billion<\/strong> (approximately <strong>USD 12.551 billion<\/strong>), representing a <strong>2.2% year-over-year increase<\/strong> (adjusted for currency and portfolio effects). <strong>Pharmaceuticals sales<\/strong> amounted to <strong>EUR 4.458 billion<\/strong> (USD 5.146 billion), roughly flat compared to the prior year (+0.8%).<\/p>\n\n\n\n<h2 id=\"h-financial-performance-snapshot\" class=\"wp-block-heading\">Financial Performance Snapshot<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Segment<\/th><th>Q2 2026 Sales<\/th><th>YoY Change<\/th><th>Key Drivers<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Group<\/strong><\/td><td>EUR 10.872B<\/td><td>+2.2%<\/td><td>Pharmaceuticals stability, Consumer Health growth<\/td><\/tr><tr><td><strong>Pharmaceuticals<\/strong><\/td><td>EUR 4.458B<\/td><td>+0.8%<\/td><td>Nubeqa (+63.9%), Kerendia (+82.9%)<\/td><\/tr><tr><td><strong>Consumer Health<\/strong><\/td><td>EUR 1.445B<\/td><td>+1.5%<\/td><td>Digestive Health (+9.4%)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-pharmaceuticals-portfolio-analysis\" class=\"wp-block-heading\">Pharmaceuticals Portfolio Analysis<\/h2>\n\n\n\n<h3 id=\"h-growth-leaders\" class=\"wp-block-heading\">Growth Leaders<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Nubeqa<\/strong> (Darolutamide): EUR 880M (+63.9% YoY)<\/li>\n\n\n\n<li>Primary driver: Higher volumes in US and European markets<\/li>\n\n\n\n<li>Indication: Prostate cancer therapy<\/li>\n\n\n\n<li><strong>Kerendia<\/strong> (Finerenone): EUR 329M (+82.9% YoY)<\/li>\n\n\n\n<li>Primary driver: Increased volume in US and China<\/li>\n\n\n\n<li>Indications: Chronic kidney disease and heart failure<\/li>\n\n\n\n<li><strong>Mirena Family<\/strong>: EUR 343M (+9.0% YoY)<\/li>\n\n\n\n<li>Primary driver: Strong US market performance<\/li>\n\n\n\n<li>Product category: Long-acting reversible contraception<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-declining-franchises-patent-expirations\" class=\"wp-block-heading\">Declining Franchises (Patent Expirations)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Xarelto<\/strong> (Rivaroxaban): EUR 374M (-42.4% YoY)<\/li>\n\n\n\n<li>Impact: Oral anticoagulant facing generic competition<\/li>\n\n\n\n<li>Status: In line with expected patent cliff<\/li>\n\n\n\n<li><strong>Eylea<\/strong> (Aflibercept): EUR 573M (-32.8% YoY)<\/li>\n\n\n\n<li>Impact: Ophthalmic drug experiencing biosimilar pressure<\/li>\n\n\n\n<li>Status: Consistent with anticipated market dynamics<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-diagnostic-imaging-growth\" class=\"wp-block-heading\">Diagnostic Imaging Growth<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ultravist<\/strong> (Iopromide): +26.8% sales growth<\/li>\n\n\n\n<li><strong>CT High-Pressure Injection Systems<\/strong>: +8.1% sales growth<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-consumer-health-segment-performance\" class=\"wp-block-heading\">Consumer Health Segment Performance<\/h2>\n\n\n\n<h3 id=\"h-category-breakdown\" class=\"wp-block-heading\">Category Breakdown<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Digestive Health<\/strong>: EUR 244M (+9.4%) \u2013 strongest performer<\/li>\n\n\n\n<li><strong>Allergy &amp; Cold<\/strong>: EUR 242M (-8.0%) \u2013 weaker seasonal demand impact<\/li>\n\n\n\n<li><strong>Other Categories<\/strong>: Positive growth across most segments<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-regional-dynamics\" class=\"wp-block-heading\">Regional Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>United States<\/strong>: Continued pressure in challenging market environment<\/li>\n\n\n\n<li><strong>Europe\/Middle East\/Africa<\/strong>: Year-over-year growth achieved<\/li>\n\n\n\n<li><strong>Latin America<\/strong>: Positive growth momentum<\/li>\n\n\n\n<li><strong>Asia-Pacific<\/strong>: Year-over-year expansion<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-portfolio-management\" class=\"wp-block-heading\">Strategic Portfolio Management<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Bayer&#8217;s Q2 performance demonstrates effective <strong>portfolio transition management<\/strong>, successfully offsetting significant patent expirations through:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation Commercialization<\/strong>: Rapid uptake of newer products (Nubeqa, Kerendia)<\/li>\n\n\n\n<li><strong>Geographic Diversification<\/strong>: Strong performance in multiple regions despite US challenges<\/li>\n\n\n\n<li><strong>Therapeutic Breadth<\/strong>: Balanced exposure across oncology, cardiorenal, women&#8217;s health, and diagnostics<\/li>\n\n\n\n<li><strong>Consumer Resilience<\/strong>: Stable over-the-counter segment providing consistent revenue base<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-outlook-amp-forward-strategy\" class=\"wp-block-heading\">Market Outlook &amp; Forward Strategy<\/h2>\n\n\n\n<h3 id=\"h-near-term-catalysts\" class=\"wp-block-heading\">Near-Term Catalysts<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Continued Nubeqa Momentum<\/strong>: Expanding prostate cancer treatment paradigm<\/li>\n\n\n\n<li><strong>Kerendia Expansion<\/strong>: Growing adoption in cardiorenal indications across major markets<\/li>\n\n\n\n<li><strong>Mirena Lifecycle Management<\/strong>: Sustained leadership in long-acting contraception<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-structural-challenges\" class=\"wp-block-heading\">Structural Challenges<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patent Cliff Navigation<\/strong>: Managing ongoing Xarelto and Eylea revenue erosion<\/li>\n\n\n\n<li><strong>US Market Pressure<\/strong>: Addressing competitive and pricing headwinds in largest pharmaceutical market<\/li>\n\n\n\n<li><strong>Seasonal Variability<\/strong>: Managing demand fluctuations in Consumer Health categories<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-strategic-priorities\" class=\"wp-block-heading\">Strategic Priorities<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation Focus<\/strong>: Accelerating development pipeline to replace declining franchises<\/li>\n\n\n\n<li><strong>Operational Efficiency<\/strong>: Cost optimization to maintain profitability during transition period<\/li>\n\n\n\n<li><strong>Geographic Balance<\/strong>: Leveraging international growth to offset regional weaknesses<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance, market dynamics, and strategic initiatives. Actual results may differ due to risks including competitive pressures, regulatory changes, market access challenges, and economic conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/bayer-half-year-financial-report-q2-2026.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of bayer-half-year-financial-report-q2-2026.\"><\/object><a id=\"wp-block-file--media-1602dd67-a73b-452c-9871-dc80adf6b009\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/bayer-half-year-financial-report-q2-2026.pdf\">bayer-half-year-financial-report-q2-2026<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/bayer-half-year-financial-report-q2-2026.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-1602dd67-a73b-452c-9871-dc80adf6b009\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Bayer AG (ETR: BAYN) released its financial results for the second quarter of 2026, reporting&#8230;<\/p>\n","protected":false},"author":1,"featured_media":71770,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[269,967,27],"class_list":["post-71768","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-bayer","tag-etr-bayn","tag-finanical-reports"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bayer Reports Q2 2026 Sales of EUR 10.87B, Driven by Strong Nubeqa and Kerendia Growth Despite Xarelto and Eylea Patent Expirations - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bayer AG (ETR: BAYN) released its financial results for the second quarter of 2026, reporting group sales of EUR 10.872 billion (approximately USD 12.551 billion), representing a 2.2% year-over-year increase (adjusted for currency and portfolio effects). Pharmaceuticals sales amounted to EUR 4.458 billion (USD 5.146 billion), roughly flat compared to the prior year (+0.8%).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71768\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer Reports Q2 2026 Sales of EUR 10.87B, Driven by Strong Nubeqa and Kerendia Growth Despite Xarelto and Eylea Patent Expirations\" \/>\n<meta property=\"og:description\" content=\"Bayer AG (ETR: BAYN) released its financial results for the second quarter of 2026, reporting group sales of EUR 10.872 billion (approximately USD 12.551 billion), representing a 2.2% year-over-year increase (adjusted for currency and portfolio effects). Pharmaceuticals sales amounted to EUR 4.458 billion (USD 5.146 billion), roughly flat compared to the prior year (+0.8%).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71768\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-05T16:23:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-05T16:23:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0507.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71768#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71768\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer Reports Q2 2026 Sales of EUR 10.87B, Driven by Strong Nubeqa and Kerendia Growth Despite Xarelto and Eylea Patent Expirations\",\"datePublished\":\"2026-08-05T16:23:22+00:00\",\"dateModified\":\"2026-08-05T16:23:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71768\"},\"wordCount\":459,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71768#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0507.webp\",\"keywords\":[\"Bayer\",\"ETR: BAYN\",\"Finanical Reports\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71768#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71768\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71768\",\"name\":\"Bayer Reports Q2 2026 Sales of EUR 10.87B, Driven by Strong Nubeqa and Kerendia Growth Despite Xarelto and Eylea Patent Expirations - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71768#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71768#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0507.webp\",\"datePublished\":\"2026-08-05T16:23:22+00:00\",\"dateModified\":\"2026-08-05T16:23:23+00:00\",\"description\":\"Bayer AG (ETR: BAYN) released its financial results for the second quarter of 2026, reporting group sales of EUR 10.872 billion (approximately USD 12.551 billion), representing a 2.2% year-over-year increase (adjusted for currency and portfolio effects). Pharmaceuticals sales amounted to EUR 4.458 billion (USD 5.146 billion), roughly flat compared to the prior year (+0.8%).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71768#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71768\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71768#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0507.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0507.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bayer Reports Q2 2026 Sales of EUR 10.87B, Driven by Strong Nubeqa and Kerendia Growth Despite Xarelto and Eylea Patent Expirations\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71768#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer Reports Q2 2026 Sales of EUR 10.87B, Driven by Strong Nubeqa and Kerendia Growth Despite Xarelto and Eylea Patent Expirations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer Reports Q2 2026 Sales of EUR 10.87B, Driven by Strong Nubeqa and Kerendia Growth Despite Xarelto and Eylea Patent Expirations - Insight, China&#039;s Pharmaceutical Industry","description":"Bayer AG (ETR: BAYN) released its financial results for the second quarter of 2026, reporting group sales of EUR 10.872 billion (approximately USD 12.551 billion), representing a 2.2% year-over-year increase (adjusted for currency and portfolio effects). Pharmaceuticals sales amounted to EUR 4.458 billion (USD 5.146 billion), roughly flat compared to the prior year (+0.8%).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71768","og_locale":"en_US","og_type":"article","og_title":"Bayer Reports Q2 2026 Sales of EUR 10.87B, Driven by Strong Nubeqa and Kerendia Growth Despite Xarelto and Eylea Patent Expirations","og_description":"Bayer AG (ETR: BAYN) released its financial results for the second quarter of 2026, reporting group sales of EUR 10.872 billion (approximately USD 12.551 billion), representing a 2.2% year-over-year increase (adjusted for currency and portfolio effects). Pharmaceuticals sales amounted to EUR 4.458 billion (USD 5.146 billion), roughly flat compared to the prior year (+0.8%).","og_url":"https:\/\/flcube.com\/?p=71768","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-05T16:23:22+00:00","article_modified_time":"2026-08-05T16:23:23+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0507.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71768#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71768"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer Reports Q2 2026 Sales of EUR 10.87B, Driven by Strong Nubeqa and Kerendia Growth Despite Xarelto and Eylea Patent Expirations","datePublished":"2026-08-05T16:23:22+00:00","dateModified":"2026-08-05T16:23:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71768"},"wordCount":459,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=71768#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0507.webp","keywords":["Bayer","ETR: BAYN","Finanical Reports"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71768#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71768","url":"https:\/\/flcube.com\/?p=71768","name":"Bayer Reports Q2 2026 Sales of EUR 10.87B, Driven by Strong Nubeqa and Kerendia Growth Despite Xarelto and Eylea Patent Expirations - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=71768#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=71768#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0507.webp","datePublished":"2026-08-05T16:23:22+00:00","dateModified":"2026-08-05T16:23:23+00:00","description":"Bayer AG (ETR: BAYN) released its financial results for the second quarter of 2026, reporting group sales of EUR 10.872 billion (approximately USD 12.551 billion), representing a 2.2% year-over-year increase (adjusted for currency and portfolio effects). Pharmaceuticals sales amounted to EUR 4.458 billion (USD 5.146 billion), roughly flat compared to the prior year (+0.8%).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71768#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71768"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=71768#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0507.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0507.webp","width":1080,"height":608,"caption":"Bayer Reports Q2 2026 Sales of EUR 10.87B, Driven by Strong Nubeqa and Kerendia Growth Despite Xarelto and Eylea Patent Expirations"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71768#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer Reports Q2 2026 Sales of EUR 10.87B, Driven by Strong Nubeqa and Kerendia Growth Despite Xarelto and Eylea Patent Expirations"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0507.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71768","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71768"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71768\/revisions"}],"predecessor-version":[{"id":71771,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71768\/revisions\/71771"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/71770"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71768"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71768"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71768"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}